VCM
PCVX icon

Versant Capital Management’s Vaxcyte PCVX Stock Holding History

Versant Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.8K Sell
753
-95
-11% -$5.16K ﹤0.01% 1452
2026
Q1 		$49.3K Buy
848
+414
+95% +$22.5K ﹤0.01% 1255
2025
Q4 		$20K Buy
434
+7
+2% +$313 ﹤0.01% 1638
2025
Q3 		$15.4K Sell
427
-1,587
-79% -$52.6K ﹤0.01% 1723
2025
Q2 		$65.5K Buy
2,014
+1,851
+1,136% +$60.7K 0.01% 846
2025
Q1 		$6.16K Buy
163
+71
+77% +$5.68K ﹤0.01% 1948
2024
Q4 		$7.53K Buy
92
+74
+411% +$7.35K ﹤0.01% 1546
2024
Q3 		$2.06K Buy
+18
New +$1.62K ﹤0.01% 1555
2023
Q3 		– Sell
-9
Closed -$449 – 2022
2023
Q2 		$449 Buy
+9
New +$427 ﹤0.01% 1860

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Versant Capital Management's PCVX Position: Q2 2026 in Review

Versant Capital Management reduced its Vaxcyte (PCVX) stake by 11% in Q2 2026, selling an estimated $5.16K and leaving 753 shares worth $43.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1452.

Versant Capital Management first reported a position in PCVX in Q2 2023 and has held it in 9 quarters since. The position peaked at $65.5K in Q2 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Versant Capital Management held 753 shares of Vaxcyte worth $43.8K as of Q2 2026.
  • Versant Capital Management sold 95 Vaxcyte shares in Q2 2026, an estimated $5.16K.
  • Vaxcyte made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1452 holding.
  • Versant Capital Management first reported a position in Vaxcyte in Q2 2023 and has held it in 9 quarters since.
  • Versant Capital Management's Vaxcyte position peaked at $65.5K in Q2 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.